APA

Kvarnhammar A. M., Veitonmäki N., Hägerbrand K., Dahlman A., Smith K. E., Fritzell S., von Schantz L., Thagesson M., Werchau D., Smedenfors K., Johansson M., Rosén A., Åberg I., Winnerstam M., Nyblom E., Barchan K., Furebring C., Norlén P. & Ellmark P. (20200707). The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. : Journal for immunotherapy of cancer.

Chicago

Kvarnhammar Anne Månsson, Veitonmäki Niina, Hägerbrand Karin, Dahlman Anna, Smith Karin Enell, Fritzell Sara, von Schantz Laura, Thagesson Mia, Werchau Doreen, Smedenfors Kristine, Johansson Maria, Rosén Anna, Åberg Ida, Winnerstam Magnus, Nyblom Eva, Barchan Karin, Furebring Christina, Norlén Per and Ellmark Peter. 20200707. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. : Journal for immunotherapy of cancer.

Harvard

Kvarnhammar A. M., Veitonmäki N., Hägerbrand K., Dahlman A., Smith K. E., Fritzell S., von Schantz L., Thagesson M., Werchau D., Smedenfors K., Johansson M., Rosén A., Åberg I., Winnerstam M., Nyblom E., Barchan K., Furebring C., Norlén P. and Ellmark P. (20200707). The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. : Journal for immunotherapy of cancer.

MLA

Kvarnhammar Anne Månsson, Veitonmäki Niina, Hägerbrand Karin, Dahlman Anna, Smith Karin Enell, Fritzell Sara, von Schantz Laura, Thagesson Mia, Werchau Doreen, Smedenfors Kristine, Johansson Maria, Rosén Anna, Åberg Ida, Winnerstam Magnus, Nyblom Eva, Barchan Karin, Furebring Christina, Norlén Per and Ellmark Peter. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. : Journal for immunotherapy of cancer. 20200707.